| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 69097-0032-56 | 69097-0032 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 18, 2025 | In Use | |
| 00003-4040-12 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec 5, 2023 | In Use | |
| 60505-2900-03 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
| 69097-0578-91 | 69097-0578 | nilotinib | NILCEYA | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2025 | In Use | |
| 59676-0030-84 | 59676-0030 | Erdafitinib | BALVERSA | 3.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Oral | Apr 12, 2019 | In Use | |
| 62332-0687-30 | 62332-0687 | DASATINIB | DASATINIB | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 11, 2025 | In Use | |
| 63539-0026-01 | 63539-0026 | Axitinib | Inlyta | 1.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 27, 2012 | In Use | |
| 65162-0794-09 | 65162-0794 | Imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | In Use | |
| 69097-0577-56 | 69097-0577 | nilotinib | NILCEYA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2025 | In Use | |
| 13668-0682-60 | 13668-0682 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Apr 12, 2023 | In Use | |
| 54868-5427-02 | 54868-5427 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 9, 2005 | Jun 30, 2013 | No Longer Used | |
| 72485-0202-90 | 72485-0202 | imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 15, 2019 | In Use | |
| 00093-7663-56 | 00093-7663 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 9, 2019 | In Use | |
| 73207-0101-30 | 73207-0101 | Ripretinib | QINLOCK | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Oral | May 15, 2020 | In Use | |
| 76189-0535-30 | 76189-0535 | Ponatinib Hydrochloride | Iclusig | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 14, 2012 | Jul 26, 2020 | No Longer Used |
| 68180-0801-36 | 68180-0801 | lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Sep 29, 2020 | In Use | |
| 76189-0535-60 | 76189-0535 | Ponatinib Hydrochloride | Iclusig | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 14, 2012 | Jul 26, 2020 | No Longer Used |
| 72579-0011-02 | 72579-0011 | Zanubrutinib | BRUKINSA | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Nov 14, 2019 | In Use | |
| 67184-0533-02 | 67184-0533 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
| 00069-8141-20 | 00069-8141 | Crizotinib | Xalkori | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | Aug 26, 2011 | In Use | |
| 69097-0577-73 | 69097-0577 | nilotinib | NILCEYA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2025 | In Use | |
| 43598-0345-05 | 43598-0345 | Imatinib | Imatinib | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 13, 2018 | In Use | |
| 69097-0578-56 | 69097-0578 | nilotinib | NILCEYA | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2025 | In Use | |
| 00054-0248-12 | 00054-0248 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2018 | In Use | |
| 51407-0760-12 | 51407-0760 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Apr 14, 2023 | In Use |
Found 12250 results — Export these results
Home